key: cord-0949328-gi6v12mi
authors: Silva Júnior, José Valter Joaquim; Merchioratto, Ingryd; de Oliveira, Pablo Sebastian Britto; Rocha Lopes, Thaísa Regina; Brites, Patrícia Chaves; de Oliveira, Elehu Moura; Weiblen, Rudi; Flores, Eduardo Furtado
title: End-point RT-PCR: a potential alternative for diagnosing coronavirus disease 2019 (COVID-19)
date: 2020-10-29
journal: J Virol Methods
DOI: 10.1016/j.jviromet.2020.114007
sha: bb43dcd3e23079b8695f69073ced2e9da93514b8
doc_id: 949328
cord_uid: gi6v12mi

Real-time reverse transcription-polymerase chain reaction (RT-qPCR) is considered the "gold standard" for the direct diagnosis of SARS-CoV-2 infections. However, routine diagnosis by RT-qPCR is a limitation for many laboratories, mainly due to the infrastructure and/or disproportionate relationship between demand and supply of inputs. In this context, and to increase the diagnostic coverage of SARS-CoV-2 infections, we describe an alternative, sensitive and specific one-step end-point RT-PCR for the detection of the SARS-CoV-2 E gene. The performance of the RT-PCR was evaluated in 43 clinical samples, of which 10 and 33 were previously identified as negative and positive, respectively, by RT-qPCR. Among the positive samples, 15 and 18 were from asymptomatic and symptomatic individuals, respectively. Here, 32/33 of the positive samples in the RT-qPCR, including from asymptomatic individuals, were found positive in the RT-PCR (Ct 15.94 to 34.92). The analytical sensitivity of the assay was about 7.15-9 copies of vRNA/μL, and nonspecific amplifications were not observed in SARS-CoV-2 negative samples. Importantly, the RT-PCR reactions were performed in a 10 μL final volume. Finally, considering specificity, analytical sensitivity and cost reduction, we believe that the RT-PCR platform described here may be a viable option for the diagnostic of SARS-CoV-2 infections in laboratories in which RT-qPCR is not available and/or not possible.

J o u r n a l P r e -p r o o f Abstract Real-time reverse transcription-polymerase chain reaction (RT-qPCR) is considered the "gold standard" for the direct diagnosis of SARS-CoV-2 infections. However, routine diagnosis by RT-qPCR is a limitation for many laboratories, mainly due to the infrastructure and/or disproportionate relationship between demand and supply of inputs. In this context, and to increase the diagnostic coverage of SARS-CoV-2 infections, we describe an alternative, sensitive and specific one-step end-point The analytical sensitivity of the assay was about 7.15-9 copies of vRNA/μL, and nonspecific amplifications were not observed in SARS-CoV-2 negative samples. Importantly, the RT-PCR reactions were performed in a 10μL final volume. Finally, considering specificity, analytical sensitivity and cost reduction, we believe that the RT-PCR platform described here may be a viable option for the diagnostic of SARS-CoV-2 infections in laboratories in which RT-qPCR is not available and/or not possible. Among the diagnostic alternatives for COVID-19, gene amplification by real-time reverse transcription-polymerase chain reaction (RT-qPCR) remains the "gold standard" for direct diagnosis. Many in-house and commercial RT-qPCR, using several and/or combined viral genes, have been proposed for molecular detection of SARS-CoV-2 (WHO, 2020b). The Charité protocol, one of the first protocols established for COVID-19 diagnosis, employs the envelope (E) and RNA dependent RNA polymerase (RdRp) genes as target for detection of SARS-CoV-2 in clinical samples (Corman et al., 2020) . However, it is also possible/reliable to diagnose COVID-19 by detecting a single genetic target. Regarding the Charité protocol, as the detection of the E gene demonstrated a slightly higher sensitivity, the Pan American Health Organization (PAHO) has recommend prioritizing the E gene as the selected target for molecular COVID-19 diagnosis (PAHO, 2020).

Unfortunately, routine diagnosis by RT-qPCR is still a limitation for many laboratories, especially in developing countries and regions. The current demand for inputs, material and equipment, associated with the few supplier companies, represents an additional (and real) obstacle for the timely diagnosis of SARS-CoV-2 infections. In this context, and in order to increase the diagnostic coverage of COVID-19, we describe a sensitive and specific protocol for the detection of the and 2min at 94°C for cDNA synthesis and pre-denaturation, respectively, followed by PCR amplification in 40 cycles of 94°C for 15s for denaturation, 52°C for 30s for annealing, 68°C for 10s for extension, followed by a final extension at 68ºC for 5min.

The total volume of the PCR reaction (10µL) was stained with GelRed (Biotium, Fremont, California, USA) and visualized under UV light on a 2% agarose gel. The J o u r n a l P r e -p r o o f analytical sensitivity was defined as the lowest concentration (highest dilution) in which it was possible to observe specific amplification.

The performance of the RT-PCR described above was evaluated in a combination of two nasopharyngeal and one oropharyngeal swab samples, according to recommendations of the Ministry of Health of Brazil (BRASIL, 2020), with genetic material extracted in the IndiMag48 automatic system (Indical Bioscience, Sachsen, Germany). We analyzed a total of 43 samples, of which 10 and 33 were previously identified as negative and positive, respectively, by the Hospital Universitário de Santa Maria (HUSM) (Rio Grande do Sul state, Brazil) by RT-qPCR targeting the SARS-CoV-2 E gene (Corman et al., 2020) . Out of the 33 positive samples, 15 were from asymptomatic individuals and 18 from symptomatic patients (Table 1) Here, the RT-PCR was able to specifically amplify the target region of the SARS-CoV-2 E gene. The 113bp amplicon, corresponding to the annealing region of the primers E_Sarbeco_F1 and E_Sarbeco_R2, precisely the 26,141-26,253nt, was clearly observed in the positive control until 7.15-9 copies of vRNA/μL (i..e. 71.5-90 copies of vRNA) ( Figure 1A) . Although this sensitivity is lower than that of the described RT-qPCR (Corman et al., 2020; Peihua et al., 2020; WHO, 2020b) Table 1 ). The RT-qPCR positive sample not detected in RT-PCR came from a symptomatic patient and showed Ct of 36.92. Nonspecific amplifications were not observed in SARS-CoV-2 negative samples ( Figure 1B ).

False-negative results have been an important concern in the RT-qPCR for SARS-CoV-2, so that several targets/primers and sample types have been evaluated to increase the sensitivity (Corman et al., 2020; Peihua et al., 2020; Tahamtana; Ardebilib, 2020; Wang et al., 2020; WHO, 2020b; Woloshin et al., 2020) . However, considering the sensitivity of these assays, it is likely that false-negative results are more related to other factors than the characteristics of the assays per se. For example, previous studies have reported that the SARS-CoV-2 viral load (or the so-called RNAemia) may vary over time and thus strongly influence the diagnosis Zheng et al., 2020; Zou et al., 2020) . Failures related to the pre-analytical phase, such as sample collection, transport and/or storage, as well as aspects of the host and the theoretical possibility of viral mutation, may also negatively influence the diagnosis of COVID-19 (Tahamtana; Ardebilib, 2020; Xiao et al., 2020) .

It is possible that the factors described above may also influence the end-point amplification, which still presented lower sensitivity than the RT-qPCR. However, we do not believe that the sensitivity represents a real limit for the implementation of a RT-PCR platform for detection of SARS-CoV-2 infection. Individuals with COVID-19 often have a high viral load, which is why the European Centre for Disease Prevention and Control (ECDC) recommends that samples with Ct >35 be J o u r n a l P r e -p r o o f retested so that the possibility of contamination is ruled out (ECDC, 2020) . A minimum concentration of about 10 copies of vRNA/μL has also been reported in respiratory samples from individuals with mild or severe COVID-19 (Pan et al., 2020; Zheng et al., 2020) . In this context, our RT-PCR showed a considerable and useful sensitivity-specificity, detecting samples with Ct 34.92, including samples from asymptomatic individuals, and not amplifying nonspecific sequences, which could require additional steps of analysis, such as gene purification and sequencing ( Figure   1 , Table 1 ). Importantly, the RT-PCR was performed in a 10μL final volume. This, in addition to not using specific inputs for RT-qPCR, can significantly reduce the cost of the assay.

Finally, when taken together, specificity, analytical sensitivity and cost, we believe that the RT-PCR platform described here may be a viable option for molecular detection of SARS-CoV-2 in laboratories in which RT-qPCR is not available and/or not possible for any reason.

Guia de Vigilância Epidemiológica Emergência de Saúde Pública de Importância Nacional pela Doença pelo Coronavírus

European Centre for Disease Prevention and Control, 2020. Questions and answers regarding laboratory topics on SARS-CoV-2

/laboratory-support/questions

Taxonomy of Viruses. Virus taxonomy: 2019 release

Pan American Health Organization, 2020. Laboratory Guidelines for the Detection and Diagnosis of COVID-19 Virus Infection

Viral load of SARS-CoV-2 in clinical samples

Three Novel Real-Time RT-PCR Assays for Detection of COVID-19 Virus

Real-time RT-PCR in COVID-19 detection: issues affecting the results

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications

World Health Organization. Coronavirus disease (COVID-19) pandemic

World Health Organization. Molecular assays to diagnose COVID-19: Summary table of available protocols

False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence

SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standards for discharge

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

A Novel Coronavirus from Patients with Pneumonia in China

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients